Literature DB >> 17121819

Soluble androgen receptor oligomers underlie pathology in a mouse model of spinobulbar muscular atrophy.

Mei Li1, Erica S Chevalier-Larsen, Diane E Merry, Marc I Diamond.   

Abstract

In polyglutamine diseases such as X-linked spinobulbar muscular atrophy (SBMA), it is unknown whether the toxic form of the protein is an insoluble or soluble aggregate or a monomer. We have addressed this question by studying a full-length androgen receptor (AR) mouse model of SBMA. We used biochemistry and atomic force microscopy to immunopurify oligomers soluble after ultracentrifugation that are comprised of a single approximately 50-kDa N-terminal polyglutamine-containing AR fragment. AR oligomers appeared several weeks prior to symptom onset, were distinct and temporally dissociated from intranuclear inclusions, and disappeared rapidly after castration, which halts disease. This is the first demonstration of soluble AR oligomers in vivo and suggests that they underlie neurodegeneration in SBMA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17121819     DOI: 10.1074/jbc.M609972200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  46 in total

Review 1.  Therapeutic approaches to spinal and bulbar muscular atrophy.

Authors:  Srikanth Ranganathan; Kenneth H Fischbeck
Journal:  Trends Pharmacol Sci       Date:  2010-09-20       Impact factor: 14.819

Review 2.  Small changes, big impact: posttranslational modifications and function of huntingtin in Huntington disease.

Authors:  Dagmar E Ehrnhoefer; Liza Sutton; Michael R Hayden
Journal:  Neuroscientist       Date:  2011-02-10       Impact factor: 7.519

Review 3.  Aggregation of expanded huntingtin in the brains of patients with Huntington disease.

Authors:  Guylaine Hoffner; Sylvie Souès; Philippe Djian
Journal:  Prion       Date:  2007 Jan-Mar       Impact factor: 3.931

Review 4.  Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy.

Authors:  Jason P Chua; Andrew P Lieberman
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-12       Impact factor: 4.388

Review 5.  α-Synuclein oligomers and clinical implications for Parkinson disease.

Authors:  Lorraine V Kalia; Suneil K Kalia; Pamela J McLean; Andres M Lozano; Anthony E Lang
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

6.  The androgen receptor's CAG/glutamine tract in mouse models of neurological disease and cancer.

Authors:  Andrew P Lieberman; Diane M Robins
Journal:  J Alzheimers Dis       Date:  2008-06       Impact factor: 4.472

Review 7.  The Role of the Protein Quality Control System in SBMA.

Authors:  Paola Rusmini; Valeria Crippa; Riccardo Cristofani; Carlo Rinaldi; Maria Elena Cicardi; Mariarita Galbiati; Serena Carra; Bilal Malik; Linda Greensmith; Angelo Poletti
Journal:  J Mol Neurosci       Date:  2015-11-14       Impact factor: 3.444

8.  F-actin binding regions on the androgen receptor and huntingtin increase aggregation and alter aggregate characteristics.

Authors:  Suzanne Angeli; Jieya Shao; Marc I Diamond
Journal:  PLoS One       Date:  2010-02-04       Impact factor: 3.240

9.  Microarray analysis of gene expression by skeletal muscle of three mouse models of Kennedy disease/spinal bulbar muscular atrophy.

Authors:  Kaiguo Mo; Zak Razak; Pengcheng Rao; Zhigang Yu; Hiroaki Adachi; Masahisa Katsuno; Gen Sobue; Andrew P Lieberman; J Timothy Westwood; D Ashley Monks
Journal:  PLoS One       Date:  2010-09-23       Impact factor: 3.240

10.  Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of Huntington's disease.

Authors:  Kirupa Sathasivam; Amin Lane; Justin Legleiter; Alice Warley; Ben Woodman; Steve Finkbeiner; Paolo Paganetti; Paul J Muchowski; Stuart Wilson; Gillian P Bates
Journal:  Hum Mol Genet       Date:  2010-01-01       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.